Hepatitis E infection with a benign course during vedolizumab treatment for Crohn's disease: A case report

Clin Res Hepatol Gastroenterol. 2022 Aug-Sep;46(7):101948. doi: 10.1016/j.clinre.2022.101948. Epub 2022 Jun 1.

Abstract

We present a 49 year old female patient with Crohn's disease (CD) in remission on vedolizumab therapy who experienced a symptomatic, though benign, course of acute hepatitis E. Routine blood tests showed substantial elevation of liver enzymes and polymerase chain reaction (PCR) testing confirmed hepatitis E virus (HEV) infection. Vedolizumab therapy was paused, liver enzymes improved three weeks after infection and normalized after six months. The patient recovered completely from mild symptoms. This case shows that hepatitis E is a potential cause of acute hepatitis during vedolizumab therapy, and in this case the infection has run a benign course.

Keywords: Crohn's disease; Hepatitis E; IBD; Vedolizumab.

Publication types

  • Case Reports

MeSH terms

  • Antibodies, Monoclonal, Humanized / adverse effects
  • Colitis, Ulcerative* / drug therapy
  • Crohn Disease* / drug therapy
  • Female
  • Gastrointestinal Agents / adverse effects
  • Hepatitis E* / diagnosis
  • Hepatitis E* / drug therapy
  • Humans
  • Middle Aged
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal, Humanized
  • Gastrointestinal Agents
  • vedolizumab